Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis
NCT03600805 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis
- Lead sponsor
- Sanofi
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- November 20, 2018
- Completion date
- November 24, 2020
- Enrollment
- 83 (actual)
- Sites
- 61
Conditions
As the registry lists them; a condition with its own page is linked.